Exocrine pancreatic insufficiency secondary to checkpoint inhibitors. A clinical case report
DOI:
https://doi.org/10.59471/202321Keywords:
Checkpoint inhibitors, Melanoma, Nivolumab, Immune-related adverse events, Pancreatitis, Exocrine pancreatic insufficiencyAbstract
Modern immunotherapy has been a flood of hope for both, patients diagnosed with cancer and for oncologists, but this has forced health professionals, within their different disciplines, to internalize and educate themselves regarding new diagnostic challenges of immunological-related adverse events (irEA), difficult to address and even more so to treat in direct proportion to their frequency of appearance. Although gastrointestinal toxicity due to immunological checkpoint inhibitors (ICI) is well known, its leading role is at the expense of enterocolitis and hepatitis, among others, relegating less than 1% to cases such as pancreatitis, where morphological and histopathological alterations , both of the ducts and of the pancreatic parenchyma, can compromise endocrine and/or exocrine function. The latter, reported in the literature only in a few cases, has a complex and difficult diagnostic approach with a flowery and disabling symptomatic sign picture, which motivates the present bibliographic review. The case of a female patient diagnosed with metastatic melanoma under treatment with nivolumab with development of exocrine pancreatic insufficiency (EPI) 7 months after suspending immunotherapy is discussed below.
References
Haanen J. B. A. G, Carbonnel F, Robert C, et al. Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of Oncology 2017;28(4):i119–i142.
Finn L, Svetomir NM, Richard J. Therapy for metastatic melanoma: the past, present, and future. BMC Medicine 2012;10:23.
Hodi FS, O’Day SJ, McDermott DF, et al. Improved Survival with Ipilimumab in Patients with Metastatic Melanoma. N Engl J Med 2010;363:711-23.
Larkin J, Chiarion‐Sileni V, Gonzalez R, et al. Five-Year Survival with Combined
Nivolumab and Ipilimumab in Advanced Melanoma. N Engl J Med 2019;381:1535-46.
Brahmer JR, Lacchetti C, Schneider BJ, et al. Management of Immune-Related
Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline. Am J Clin Oncol 2018;36(17):1714-1772.
Khoja L, Day D, Wei-Wu Chen T, et al. Tumour- and class-specific patterns of immune-related adverse events of immune checkpoint inhibitors: a systematic review. Annals of Oncology 2017;28:2377–2385.
Liu Y, Zhang H, Zhou L, et al. Immunotherapy-Associated Pancreatic Adverse Events: Current Understanding of Their Mechanism, Diagnosis, and Management. Front. Oncol. 2021;11:627612.
Sweepa B, Wilgenhofb S, Antena S. Nivolumab-Induced Exocrine Pancreatic Insufficiency. Case Rep Oncol 2021;14:1627–1631.
Cramer P, Bresalier RS. Gastrointestinal and Hepatic Complications of Immune Checkpoint Inhibitors. Curr Gastroenterol Rep 2017;19:3.
Eigentler TK, Hassel JC, Berking C, et al. Diagnosis, monitoring and management of immune-related adverse drug reactions of anti-PD-1 antibody therapy. Cancer Treatment Reviews 2016;45:7–18.
Dehghani L, Mikail N, Kramkimel N, et al. Autoimmune pancreatitis after nivolumab anti programmed death receptor-1 treatment. European Journal of Cancer 2018;1-4.
George J, Bajaj D, Sankaramangalam K, et al. Incidence of pancreatitis with the use of immune checkpoint inhibitors (ICI) in advanced cancers: A systematic review and meta-analysis. Pancreatology 2019; 19:587-594.
Cheemaa A, Makadiaa B, Karwadiaa T, et al. Autoimmune Diabetes Associated With Pembrolizumab: A Review of Published Case Reports. World J Oncol 2018;9(1):1-4.
Eshet Y, Baruch EN, Shapira-Frommer R, et al. Clinical Significance of Pancreatic Atrophy Induced by Immune-Checkpoint Inhibitors: A Case–Control Study. Cancer Immunol Res 2018;6(12):1453-1458.
Domínguez Muñoz JE. Fisiopatología, diagnóstico y tratamiento de la insuficiencia pancreática exocrina en el paciente con pancreatitis crónica. Gastroenterol Hepatol 2005;28(2):22-8.
Basso S, Canicoba M, Capitanich P, et al. I Consenso argentino de diagnóstico y tratamiento de la insuficiencia pancreática exocrina. Acta Gastroenterol Latinoam 2018;48(3):213-225.
Loser C, Mollgaard A, Folsch UR. Faecal elastase 1: a novel, highly sensitive, and specific tubeless pancreatic function test. Gut 1996;39:580-586.
Prasanna T, McNeil CM, Nielsen T, et al. Isolated immune-related pancreatic exocrine insufficiency associated with pembrolizumab therapy. Immunotherapy 2018;10(3):171–175.
Collins M, Michot JM, Danlos FX, et al. Inflammatory gastrointestinal diseases associated with PD-1 blockade antibodies. Annals of Oncology 2017;28:2860–2865.
Published
Issue
Section
License
Copyright (c) 2023 María Paula Pinto, Janeth Lara Alcántara, Gabriela Comesaña, Johanna Ayeray Costa, Ian Hirsch, Lucia Piñon, Patricio Servienti (Author)
This work is licensed under a Creative Commons Attribution 4.0 International License.
The article is distributed under the Creative Commons Attribution 4.0 License. Unless otherwise stated, associated published material is distributed under the same licence.
How to Cite
